Your patients don’t see a protocol.
They see a headline, an image, a landing page, a screener question, a call, and a decision:
Is this worth my time?
That first interaction shapes what they understand before a site ever speaks with them. It tells them whether the study feels relevant, credible, and clear enough to continue.
That gap matters because clinical trial recruitment doesn’t only compete for attention. It competes for understanding.
A protocol can define eligibility, sites, timelines, and endpoints. But patients make choices based on the version of the study placed in front of them.
If that version feels vague, overly clinical, or disconnected from how patients think, early response becomes harder to trust.
Patients need to understand quickly:
When the message is unclear, a campaign can still generate clicks. But clicks alone don’t prove recruitment readiness.
The way a study is presented shapes who responds, who continues, and who self-selects out before the sponsor ever reviews the signal.
This includes the language, visuals, trust signals, landing page flow, screener framing, and call to action that shape how patients interpret the study.
A clear study presentation helps the right patients recognize themselves and move forward with more confidence.
A weak presentation can create broad interest without qualified progression. It also causes eligible patients to hesitate, misunderstand, or abandon the process too early.
That means early recruitment data can reflect more than protocol fit.
It can reflect message clarity.
Antidote’s Market Feasibility Test helps sponsors test market response before recruitment begins.
An MFT can show whether the right patients are reachable, whether the message is clear, where qualification narrows, and whether early interest holds up against the protocol.
A strong protocol deserves more than assumed market readiness.
It deserves evidence from the people it needs to reach.